Cylene Pharmaceuticals Appoints David M. Ryckman, Ph.D. as Vice President of Manufacturing and Pharmaceutical Operations

San Diego, CA - July 10, 2007

Cylene Pharmaceuticals is pleased to announce the addition of Dr. David M. Ryckman to its management team, where he will serve as Vice President of Manufacturing and Pharmaceutical Operations. With nearly 20 years of experience in developing formulation and process chemistries, Dr. Ryckman will lead Cylene’s scale-up and manufacturing operations.

“I’m happy to be joining Cylene’s exceptional management team, and I look forward to developing world-class commercial pharmaceutical capabilities,” said Dr. Ryckman. “This is an exciting time as we enter Phase II clinical studies.”

Dr. Ryckman joined Cylene from Myogen, Inc., where he was responsible for pharmaceutical operations and manufacturing. Prior to his work at Myogen, Dr. Ryckman was the Site Director and Director of Chemical Operations for Chiron Corp; he has also worked in technology and chemistry with AlliedSignal (now Honeywell), Gensia Pharmaceuticals and SmithKline Beecham Pharmaceuticals.

“We’re very fortunate to have Dr. Ryckman here to guide Cylene’s manufacturing and pharmaceutical processes,” said Dr. William Rice, Cylene’s President and Chief Executive Officer. “Dr. Ryckman’s expertise in chemistry and his experience in delivering drugs for regulated studies make him a significant asset to our team as we enter the next stage of our company’s evolution.”

Dr Ryckman earned a Ph.D. in organic chemistry from the University of California, Los Angeles, and he completed a postdoctoral research fellowship in chemistry at Harvard University.

About Cylene Pharmaceuticals, Inc.
Cylene Pharmaceuticals is a pharmaceutical company dedicated to the discovery, development and commercialization of targeted small-molecule drugs to treat life-threatening cancers. Using its proprietary Ribosomal RNA Biogenesis Inhibition Technology (RABIT™) to design molecules that combat drug-resistant forms of cancer, Cylene has created multiple product candidates in different stages of development. Cylene’s most advanced cancer agent, Quarfloxin (CX-3543), is a Ribosomal RNA Biogenesis Inhibitor (RBI) in Phase II clinical development in chronic lymphocytic leukemia and late-stage Phase I development in solid tumors. More information can be found at www.cylenepharma.com.

Company Contact:
William Rice, Ph.D.
President and CEO
Cylene Pharmaceuticals
858-875-5100
wrice@cylenepharma.com

Media Contact:
Karen Sparks
Mentus
858-455-5500 x275
karen@mentus.com